Study · Indexing hint: Animal study · 2019
RetractedLixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways.
Guo NF, Cao YJ, Chen X, Zhang Y, Fan YP, Liu J, Chen XL
European review for medical and pharmacological sciences1 May 2019Cited by 17 (Europe PMC)
The journal or the authors withdrew this study after publication. Read the notice for the reason. PepBank keeps the study listed. Its results never count as key results, in evidence counts or in charts.
- Retraction notice on PubMed (PMID 37522656) (opens in a new tab)Retraction notice, Europe PMC, seen 27 Oct 2026
Summary
The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)
Text rights: Publisher copyright. Results still quote short attributed sentences.
No results listed for this study
This study is retracted. Results from a retracted study never count as evidence.
Version history
PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.
Version 2Current
27 Oct 2026, 16:37 UTC
Status changed: status, notices · status retracted · status notice from Retraction Watch (Crossref)
Version 1
27 Oct 2026, 16:36 UTC
First added · status retracted · source update from Europe PMC
Subjects
Terms as the source lists them.
Publication types
PepBank is a research reference. Talk to a doctor before you use any peptide.